BTIG Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $14

Benzinga · 05/09 19:10
BTIG analyst Robert Hazlett maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and raises the price target from $7 to $14.